<DOC>
	<DOCNO>NCT01811485</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety LMF237 50/250 mg 50/500 mg bid Japanese patient T2DM inadequately control vildagliptin monotherapy . This study conduct support registration fixed-dose combination vildagliptin metformin treatment T2DM Japan .</brief_summary>
	<brief_title>Study Efficacy Safety LMF237 Patients With Type 2 Diabetes Mellitus ( T2DM ) Inadequately Controlled With Vildagliptin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients type 2 diabetes inadequately control diet , exercise oral antidiabetic therapy HbA1c range 7.010.0 % Body mass index range 2035 kg/m^2 Type 1 diabetes , monogenic diabetes , diabetes result pancreatic injury , secondary form diabetes Significant heart diseases Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>